RSV

Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, O'Brien KL. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr Infect Dis J. 2008; 27(3):207-12.

Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB Collins PL, O'Shea AF, Gruber WC, Murphy BR. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine. 2007; 25(42):7372-8.

Wright PF, Deatly AM, Karron RA, Beishe RB, Shi JR, Gruber WC, Zhu Y, Randolph VB. Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness. J Clin Microbiol. 2007 Jul 45(7):2126-9.

Melendi GA, Hoffman SJ, Karron RA, Irusta PM, Laham FR, Humbles A, Schofield B, Pan CH, Rabold R, Thumar B, Thumar A, Gerard NP, Mitzner W, Barnum SR, Gerard C, Kleeberger SR, Polack FP.C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.J Virol. 2007 Jan;81(2):991-9. Epub 2006 Nov 1.

Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O’Shea A, Ikizler MR, Zhu Y, Collins PL, Cutland C, Randolph VB, Deatly AM, Hackell JG, Gruber WC, Murphy BR. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis. 2006 Feb 15; 193(4):573-81.

Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005; (7):1116-1122.

Harcourt JL, Karron RA, Tripp RA. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis. 2004 Dec 1(11); 190:1936-40.

Polack FP, Teng M, Kleeberger S, Hoffman SJ, Collins P, Wills-Karp M, Prince G, Karron RA. A role for immune complexes in enhanced respiratory syncytial virus disease.J Exp Med. 2002; 196:859-65.

Wright PF, Karron R, Belshe RB, Thompson J, Crowe JE, Boyce TG, Halburnt LL, Reed GW,Whitehead SS, Anderson EA, Wittek AC, Casey R, Eichelberger M, Thumar B, Randolph VB,Udem SA, Murphy BR. Evaluation of a Live, Cold-Passaged, Temperature-Sensitive, Respiratory Syncytial Virus (RSV) Vaccine in Infancy. J Infect Dis. 2000; 182(5):1331-1342.

Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR. Evaluation of the live attenuated cpts248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine. 2000; 18:1763-1722.

Karron RA, Singleton RJ, Bulkow L, Parkinson A, Kruse D, DeSmet I, Indorf C, Petersen KM, Leombruno D, Hurlburt D, Santosham M, Harrison LH, for the RSV Alaska Study Group. Severe respiratory syncytial virus disease in Alaska Native Children. J Infect Dis. 1999; 180 (1):41-9.

Karron RA, Wright PF, Crowe JE Jr, Clements ML, Thompson J, Makhene M, Casey R, Murphy BR. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J Infect Dis. 1997; 176:1428-37.

Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS. Respiratory syncytial virus SH and G proteins are not essential for viral replication in vitro clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.Proc Natl Acad Sci. 1997; 94:13961-66.